Phaseline

Targets › F3

F3 (Tissue factor): drug programs, companies and trials

5 programs from 4 companies in 5 trials: 2 Phase 2, 2 Phase 1, 1 Phase 4; Oncology, Neurology; next expected readout Mar 2027.

Initiates blood coagulation by forming a complex with circulating factor VII or VIIa. The [TF:VIIa] complex activates factors IX or X by specific limited proteolysis. (UniProt, P13726)

Open in Phaseline: the race on F3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
PfizerTisotumab Vedotin
Tubulin inhibitor; Coagulation factor III binding agent
Tubulin, F3Phase 4Cervical CancerDec 2028
Pfizertisotumab vedotin
Tubulin inhibitor; Coagulation factor III binding agent
Tubulin, F3Phase 2Colorectal NeoplasmsMar 2027
Zhujiang HospitalBevifibatide citrate injection
Tissue factor pathway inhibitor (TFPI) analog
F3Phase 2Ischemic Stroke, Acute–
Adcendo ApSADCE-T02
Tissue factor targeted antibody-drug conjugate
F3Phase 1Advanced Solid TumorMar 2027
Sutro BiopharmaSTRO-004
Tissue Factor (TF) antagonist; antibody-drug conjugate targeting TF-expressing cancer cell
F3Phase 1Head and Neck Squamous Cell Carcinoma HNSCCDec 2027

Conditions

Colorectal Neoplasms (1) Cervical Cancer (1) Head and Neck Squamous Cell Carcinoma HNSCC (1) Ischemic Stroke, Acute (1) Advanced Solid Tumor (1)

Modalities

mixed (2), small molecule (2), protein or peptide (1)

Companies

Pfizer (2) Sutro Biopharma (1) Zhujiang Hospital (1) Adcendo ApS (1)

Related targets

Tubulin (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.